CoLiQ is a clinical study designed to evaluate the clinical usefulness of circulating tumor DNA (ctDNA) markers found in blood, as a liquid biopsy for diagnosis, prognosis and follow-up of colorectal cancer. The main questions it aims to answer are: 1) Can a panel of ctDNA markers identify CRC patients among the other patients summoned for colonoscopy? and 2) Does the type, number and level of ctDNA markers vary with the subtype and clinical course of CRC? Participants will be asked to answer a questionnaire and give a blood sample at inclusion. In addition, patients with CRC will be asked to give an extra test tube at their routine treatment and follow-up blood sampling.
Patient ≥ 18 years old summoned for colonoscopy
Patient able to understand and sign written informed consent
Patient < 18 years old
Patient unable to understand or give written informed consent
Patient unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator as unlikely to complete the study
Patients summoned for colonoscopy at their local public hospital
Case-control
Prospective
liquid biopsy
Diagnostic testbased on a panel of circulating tumor DNA markers
Colorectal cancer
Number of patients with colorectal cancer at histology following colonoscopy
Colorectal adenoma
Number of patients with colorectal adenoma at histology following colonoscopy
Inflammatory bowel disease
Number of patients with inflammatory bowel disease at histology following colonoscopy
Recurrence
Recurrence of colorectal cancer among patients treated curatively.
Death
Death among patients with colorectal cancer
Treatment response
Treatment response among colorectal cancer patients as measured by todays standards of follow-up (CEA, CT-scans, colonoscopy)
Click on the lead sponsor to view all of their trials.
Helse Nord-Trøndelag HF
Lead sponsor
Norwegian University of Science and Technology
Collaborator
